The Adrenal Medulla and Catecholamines

The adrenal gland has two functionally and embryologically separate parts wrapped into one organ: an outer adrenal cortex, which secretes steroid hormones (cortisol, aldosterone, androgens) under slower control, and an inner adrenal medulla, which is the focus here. The adrenal medulla is composed of chromaffin cells, so named because they stain readily with chromium salts. These cells derive from the neural crest, the same embryonic lineage that gives rise to postganglionic sympathetic neurons. In fact, chromaffin cells are best understood as postganglionic sympathetic neurons that never grew axons; instead of releasing neurotransmitter onto an adjacent target cell across a synapse, they release their chemical contents into fenestrated capillaries that drain into the general circulation. This is why the adrenal medulla is often called a "specialized sympathetic ganglion" — it retains the preganglionic cholinergic input typical of the sympathetic chain but discards the postganglionic axon in favor of endocrine secretion. The two catecholamines released, epinephrine and norepinephrine, are synthesized from the amino acid tyrosine through a conserved four-step pathway (tyrosine → L-DOPA → dopamine → norepinephrine → epinephrine), with the final methylation step occurring almost exclusively in adrenal chromaffin cells because it requires the enzyme phenylethanolamine-N-methyltransferase (PNMT), whose expression is induced by high local concentrations of cortisol delivered from the surrounding cortex through a portal blood supply. This anatomical arrangement — cortisol-rich blood draining past medullary cells before leaving the gland — explains why roughly 80% of adrenal medullary output is epinephrine and only about 20% is norepinephrine, whereas sympathetic nerve terminals throughout the rest of the body release almost exclusively norepinephrine as a neurotransmitter, not epinephrine. The functional distinction that must be kept precise: norepinephrine acts predominantly as a neurotransmitter, released locally at sympathetic nerve endings to act on immediately adjacent target cells, while epinephrine (and the smaller adrenal norepinephrine contribution) acts as a hormone, traveling through the blood to reach adrenergic receptors on virtually every tissue in the body simultaneously. The adrenal medulla thus amplifies and generalizes the sympathetic nervous system's local, wired effects into a global, humoral one — the physiological basis of a whole-body "fight-or-flight" response rather than a series of isolated local adjustments.

Step 1 — Central trigger. A perceived threat, fear stimulus, hypoglycemia, hemorrhage, or exercise is processed by the hypothalamus and brainstem, which increase output along descending sympathetic pathways. Preganglionic sympathetic neurons originating in the thoracic spinal cord (levels T5–T11 primarily) send myelinated axons through the splanchnic nerves directly to the adrenal medulla, bypassing the usual sympathetic ganglion synapse.

Step 2 — Cholinergic activation of chromaffin cells. These preganglionic fibers release acetylcholine onto chromaffin cells, acting on nicotinic acetylcholine receptors (ligand-gated cation channels). This depolarizes the chromaffin cell membrane, opening voltage-gated Ca²⁺ channels.

Step 3 — Calcium-triggered exocytosis. The resulting rise in intracellular Ca²⁺ triggers fusion of catecholamine-containing secretory granules ("chromaffin granules") with the plasma membrane, releasing their contents — epinephrine, norepinephrine, ATP, chromogranins, and some enkephalins — directly into the capillary bed of the medulla, mechanistically identical to how Ca²⁺ triggers neurotransmitter release at a conventional synapse.

Step 4 — Systemic distribution. Catecholamines enter the general circulation via the adrenal vein and reach target tissues within seconds, with a plasma half-life of only 1–3 minutes — they are rapidly degraded by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT), mainly in the liver, which is why the response is fast to turn on and fast to turn off once sympathetic drive subsides.

Step 5 — Receptor-specific target effects. Circulating epinephrine and norepinephrine bind adrenergic receptors, a family of G-protein-coupled receptors with distinct subtypes and distinct — sometimes opposite — downstream effects depending on which G protein each subtype recruits.

Epinephrine binds α and β receptors with roughly comparable, high affinity, giving it broad systemic reach; norepinephrine binds α receptors strongly but β₁ only moderately and β₂ very weakly — this is why norepinephrine (used clinically as a pressor) causes strong vasoconstriction with relatively less bronchodilation or skeletal-muscle vasodilation than epinephrine does.

Step 6 — Organ-level integration. The net "fight-or-flight" pattern emerges from receptor distribution, not from a single master switch:

• Heart: β₁ stimulation increases heart rate (chronotropy), contractility (inotropy), and conduction velocity, raising cardiac output.
• Blood vessels: α₁-mediated vasoconstriction in skin, mucosa, and splanchnic (gut) circulation shunts blood away from digestion and non-essential surfaces; β₂-mediated vasodilation in skeletal muscle and coronary vessels increases flow exactly where oxygen demand is about to rise. Because skeletal muscle vasculature carries both α₁ and β₂ receptors, the net effect at physiological epinephrine concentrations is often vasodilation, since β₂ affinity for epinephrine is higher.
• Lungs: β₂-mediated bronchodilation lowers airway resistance, increasing oxygen delivery capacity.
• Liver: β₂ (and to a lesser extent α₁) stimulation activates glycogen phosphorylase via the cAMP–protein kinase A cascade, driving glycogenolysis and gluconeogenesis, raising blood glucose within minutes.
• Adipose tissue: β₃ stimulation activates hormone-sensitive lipase, releasing free fatty acids and glycerol for oxidation by working muscle.
• Pancreas: α₂ stimulation suppresses insulin secretion from β-cells (preventing glucose from being driven back into storage precisely when it is needed in blood) while β₂ stimulation modestly promotes glucagon secretion — catecholamines are functionally hyperglycemic hormones, working in the opposite direction from insulin, foreshadowing the interplay covered in Glucose Homeostasis and the Endocrine Pancreas.
• Eye: α₁ stimulation contracts the iris radial muscle, dilating the pupil (mydriasis) to maximize visual field and light gathering.
• Skeletal muscle: β₂-mediated glycogenolysis and vasodilation prepare the tissue for immediate contractile work, while tremor can result from direct β₂ effects on muscle spindle activity.

Walter Cannon and the concept of sympathoadrenal activation (1910s–1930s). Walter Bradford Cannon, working at Harvard, performed a series of experiments on cats exposed to a barking dog or other threats. He showed that stimulation of the splanchnic nerve caused the adrenal gland to secrete a substance that mimicked the effects of direct sympathetic nerve stimulation elsewhere in the body — accelerating heart rate, raising blood glucose, and inhibiting gut motility even in organs with no direct nerve connection to the stimulated splanchnic nerve. Cannon demonstrated that denervated organs (surgically isolated from direct nerve supply, but still supplied by blood) still responded to emotional or physical stress, proving that a blood-borne factor, not only direct innervation, mediated the response. This led him to coin the term "fight-or-flight" and to propose the concept of "sympathin," a chemical mediator released into the blood that could reproduce sympathetic effects at a distance — later identified as epinephrine and norepinephrine. Cannon also developed the concept of homeostasis, arguing that the sympathoadrenal system exists to rapidly restore internal stability after a disturbance.

Elliott's early hypothesis (1904) and Oliver & Schäfer (1894). Even before Cannon, George Oliver and Edward Schäfer had shown that adrenal extract injected intravenously raised blood pressure dramatically, demonstrating a potent circulating pressor substance from the gland. T. R. Elliott then proposed in 1904 that this substance (adrenaline, isolated and named shortly before) might be the chemical released by sympathetic nerve endings themselves — an early and remarkably prescient anticipation of the neurotransmitter concept, later confirmed for norepinephrine specifically by Ulf von Euler in 1946, who identified norepinephrine (not epinephrine) as the principal transmitter at sympathetic nerve terminals, distinguishing local neurotransmission from adrenal medullary hormone secretion. Von Euler's work, for which he shared the 1970 Nobel Prize in Physiology or Medicine (with Julius Axelrod and Bernard Katz), was essential in establishing that the adrenal medulla and peripheral sympathetic nerve terminals, while releasing overlapping chemicals, are functionally and quantitatively distinct systems.

Modern confirmation via selective denervation and receptor blockade. Twentieth-century pharmacology confirmed Cannon's model with precision: adrenalectomized animals (adrenal medulla removed) still mount a sympathetic response to stress via direct nerve-mediated norepinephrine release, but lose the rapid, large-scale rise in circulating epinephrine and its associated hyperglycemia — demonstrating that the adrenal medulla contributes a specific, large-magnitude, blood-glucose-mobilizing component that direct innervation alone cannot fully replicate. Selective receptor antagonists (α-blockers like phentolamine, β-blockers like propranolol) applied in isolated organ preparations dissected out which specific receptor subtype mediated which effect — for example, showing that isoproterenol (a pure β-agonist) reproduces bronchodilation and tachycardia but not vasoconstriction, while phenylephrine (a pure α₁-agonist) reproduces vasoconstriction and mydriasis but not tachycardia. This receptor-subtype dissection, built on the original α/β classification proposed by Raymond Ahlquist in 1948 based on differing potency orders of catecholamine analogs across tissues, is what converted Cannon's single "sympathin" into the modern multi-receptor framework described above.

Example 1 — Predicting the net vascular response in skeletal muscle during exercise onset. A 70 kg runner begins a sprint. Sympathetic drive rises sharply, and adrenal epinephrine secretion increases roughly tenfold above resting plasma levels within 30 seconds (from a resting ~30 pg/mL to over 300 pg/mL during intense exertion). Skeletal muscle vasculature expresses both α₁ receptors (vasoconstrictor) and β₂ receptors (vasodilator). Epinephrine binds β₂ receptors with substantially higher affinity than α₁ receptors at physiological concentrations. Predict the net effect on skeletal muscle blood flow, and contrast it with skin blood flow, which expresses predominantly α₁ receptors. Reasoning: Because epinephrine preferentially activates β₂ at the low-to-moderate concentrations reached early in exercise, skeletal muscle arterioles dilate, increasing local blood flow precisely where oxygen and glucose demand are rising. In skin, which lacks significant β₂ receptor density, the same circulating epinephrine (plus direct sympathetic norepinephrine release) acts almost exclusively on α₁ receptors, producing vasoconstriction — consistent with the pale, cool skin often observed during acute stress or exercise. This receptor-density argument, not a difference in the hormone itself, explains why one circulating signal produces opposite vascular outcomes in two tissues simultaneously — a clean illustration of the general principle that hormone action is determined by the receptor repertoire of the target cell, not solely by hormone identity or concentration.

Example 2 — Diagnosing pheochromocytoma from a clinical vignette. A 42-year-old patient presents with episodic attacks of severe headache, palpitations, profuse sweating, and blood pressure spikes to 220/130 mmHg lasting 15–20 minutes, occurring roughly twice a week, with normal blood pressure between episodes. Urinary metanephrines (catecholamine breakdown products) are markedly elevated: 24-hour urinary normetanephrine = 1800 μg (normal upper limit ≈ 900 μg). A CT scan reveals a 3 cm adrenal mass. Reasoning: The episodic, paroxysmal nature of the symptoms (rather than sustained hypertension) points toward intermittent catecholamine release from a tumor of chromaffin cell origin — a pheochromocytoma — rather than essential hypertension or an aldosterone-secreting adenoma (which would cause sustained hypertension with hypokalemia, not episodic surges). The triad of headache, palpitations, and diaphoresis reflects, respectively, α₁-mediated vasoconstriction/hypertension, β₁-mediated tachycardia, and sympathetic cholinergic sweat gland activation. Elevated urinary normetanephrine (the O-methylated metabolite of norepinephrine) confirms excess catecholamine production and metabolism, since catecholamines themselves are too rapidly cleared (half-life 1–3 minutes) to reliably measure directly in a spot sample, whereas their metabolites accumulate and are stable over the 24-hour collection. Management requires α-blockade before β-blockade (e.g., phenoxybenzamine started days before any β-blocker): giving a β-blocker first would remove the β₂-mediated vasodilation that partially offsets α₁ vasoconstriction, leaving unopposed α₁ vasoconstriction and precipitating a hypertensive crisis — a direct, high-stakes clinical application of understanding which receptor subtype opposes which.

Walter Cannon trained as a physiologist under Henry Pickering Bowditch at Harvard and spent his career investigating how the body maintains internal stability under external disturbance. Using X-ray fluoroscopy, he first studied gastrointestinal motility in cats, noticing that fear or rage abruptly halted digestive movements — an observation that launched decades of work on the physiological signature of emotional and physical stress. Cannon's meticulous surgical experiments — cutting specific nerves, denervating organs, sampling adrenal venous blood, and comparing responses in normal versus adrenalectomized animals — established with unusual rigor for his era that a blood-borne chemical, not nerve impulses alone, mediated many of the widespread bodily changes accompanying stress. He extended this into the broader concept of homeostasis, borrowing and popularizing the term to describe the coordinated physiological mechanisms (including but not limited to the sympathoadrenal system) that resist disturbance to internal conditions. His 1932 book The Wisdom of the Body remains a landmark synthesis connecting this cellular and organ-level physiology to whole-organism resilience, and his framework still organizes how physiology courses teach the stress response today.

Emergency medicine. Epinephrine is first-line treatment for anaphylaxis (intramuscular injection, e.g., EpiPen), rapidly reversing airway constriction (β₂), low blood pressure (α₁ vasoconstriction restoring perfusion), and vascular leakage. It is also used in cardiac arrest resuscitation protocols to improve coronary and cerebral perfusion pressure via α₁-mediated vasoconstriction of non-essential vascular beds during CPR.

Cardiology and hypertension. β-blockers (β₁-selective agents like metoprolol or atenolol) reduce heart rate and myocardial oxygen demand in ischemic heart disease and control arrhythmias by blunting β₁ signaling; α₁-blockers (e.g., prazosin) treat hypertension and benign prostatic hyperplasia by reducing vascular and smooth-muscle tone.

Pulmonology. Selective β₂-agonists (albuterol, salmeterol) are mainstay bronchodilator therapy for asthma and COPD, exploiting the same receptor subtype responsible for exercise-induced bronchodilation.

Endocrinology and oncology. Pheochromocytoma and paraganglioma (extra-adrenal chromaffin tumors) are diagnosed via elevated plasma or urinary metanephrines and imaging, and managed surgically after careful sequential α- then β-blockade to prevent hypertensive crisis during tumor manipulation.

Anesthesia and surgery. Local anesthetics are frequently combined with epinephrine to cause local vasoconstriction (α₁), reducing bleeding and slowing anesthetic clearance from the injection site, prolonging effect.

Sports physiology and metabolic research. Understanding catecholamine-driven glycogenolysis and lipolysis informs research on exercise metabolism, doping detection (exogenous catecholamine analogs), and the physiological basis of stress hyperglycemia seen in critically ill patients, connecting directly to the broader hormonal regulation of blood glucose covered under Glucose Homeostasis and the Endocrine Pancreas and the slower, cortisol-mediated stress axis in Stress and the HPA Axis.

Ask the tutor: How does the adrenal medulla's fast catecholamine response coordinate with the slower cortisol-driven HPA axis during a sustained stressor?